BridgeBio Pharma (FRA:2CL) Net Margin %: -84.33% (As of Mar. 2026)


FRA:2CL BridgeBio Pharma Inc FRA:2CL
66 GF Score
Price €60.30
GF Value €121.36
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is BridgeBio Pharma Net Margin %?

BridgeBio Pharma FRA:2CL +0.03% 66 Net Margin % is -84.33% as of Mar. 2026. GuruFocus rates FRA:2CL with a GF Score™ of 66/100 and a GF Value™ of €121.36 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 947 Biotechnology companies, BridgeBio Pharma ranks worse than 53.54% on this metric.

Net margin is calculated as Net Income divided by its Revenue. BridgeBio Pharma's Net Income for the three months ended in Mar. 2026 was €-141.9 Mil. BridgeBio Pharma's Revenue for the three months ended in Mar. 2026 was €168.3 Mil. Therefore, BridgeBio Pharma's net margin for the quarter that ended in Mar. 2026 was -84.33%.

The historical rank and industry rank for BridgeBio Pharma's Net Margin % or its related term are showing as below:

FRA:2CL' s Net Margin % Range Over the Past 10 Years
Min: -6913.92   Med: -642.47   Max: -124.42
Current: -124.42

FRA:2CL's Net Margin % is ranked worse than
53.54% of 947 companies
in the Biotechnology industry
Industry Median: -89.33 vs FRA:2CL: -124.42

BridgeBio Pharma  (FRA:2CL) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

BridgeBio Pharma Net Margin % Related Terms

BridgeBio Pharma Net Margin % Historical Data

* Premium members only.

The historical data trend for BridgeBio Pharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Pharma Net Margin % Chart

BridgeBio Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only -806.90 -619.70 -6,913.80 -241.44 -144.39

BridgeBio Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -143.55 -164.52 -151.40 -125.09 -84.33

FRA:2CL vs EXEL, IONS, SMMT: Net Margin % Comparison

For the Biotechnology subindustry, BridgeBio Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Pharma Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's Net Margin % falls into.


FRA:2CL
66GF Score
BridgeBio Pharma Inc FRA:2CL
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Pharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

BridgeBio Pharma's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-619.091/428.773
=-144.39 %

BridgeBio Pharma's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-141.897/168.255
=-84.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -84.33% mean?
BridgeBio Pharma (FRA:2CL) has a Net Margin % of -84.33% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on BridgeBio Pharma and its competitors. According to the industry distribution chart, BridgeBio Pharma ranks #507 out of 947 companies in the Biotechnology industry, placing it in the top 53.5%.
Is BridgeBio Pharma's Net Margin % too high?
BridgeBio Pharma's current Net Margin % is -84.33%. Based on the distribution chart, BridgeBio Pharma ranks #507 out of 947 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BridgeBio Pharma has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's Net Margin % compare to EXEL and IONS?
According to the Biotechnology industry distribution chart, BridgeBio Pharma ranks #507 out of 947 companies for Net Margin %. This places BridgeBio Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on BridgeBio Pharma and its competitors. BridgeBio Pharma's current Net Margin % is -84.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €121.36, compared to a current price of €60.30 — trading 50.3% below its estimated fair value. The current Net Margin % is -84.33%. BridgeBio Pharma's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current Net Margin % is -84.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?

Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued. The current stock price of €60.30 is trading 50.3% below its estimated GF Value™ of €121.36. GuruFocus considers BridgeBio Pharma to be Possible Value Trap.

Key valuation signals for FRA:2CL:

  • Net Margin %: -84.33%
  • GF Value™: €121.36 vs. price of €60.30 (50.3% below fair value)
  • GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BridgeBio Pharma Business Description

Other Exchanges BBIO:USA1BBIO:Italy
Address 3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
66GF Score

Get the complete analysis for FRA:2CL

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€60.30
Price
€121.36
GF Value